EUVIMEDEUVIMED entdecken
Open Access

WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go?

Shakthivel Mani, Abhishek Chatterjee, Archya Dasgupta, Neelam Shirsat, Sridhar Epari, Girish Chinnaswamy, Tejpal Gupta

Oncotarget · 07.02.2023 · 14 (1) · 105-110

DOI: 10.18632/oncotarget.28360 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncotarget, online erschienen am 07.02.2023. Verfasst von Shakthivel Mani und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, ACTREC/TMH, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra 410210, India. Hauptthemen laut MEDLINE: Cerebellar Neoplasms, Medulloblastoma. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Novel biological insights have established that medulloblastoma is a heterogenous disease comprising four broad molecular subgroups - WNT, SHH, Group 3, and Group 4 respectively, resulting in the incorporation of molecular/genetic information in 5th edition of WHO classification and contemporary risk-stratification. Concerns regarding therapy-related late toxicity in long-term survivors have led to systematic attempts at treatment de-intensification in good-risk medulloblastoma. Given the excellent survival (>90%) of WNT-pathway medulloblastoma, prospective clinical trials have focused on optimization of therapy to balance survival versus quality of survival. The currently accepted definition of low-risk WNT-pathway medulloblastoma includes children 15 years). Despite modest differences in disease status at presentation and treatment modality, there were no significant differences in patterns of failure or survival between childhood versus adolescent and young adult WNT-pathway medulloblastoma. Two de-intensification trials in low-risk WNT-pathway medulloblastoma - first testing omission of upfront craniospinal irradiation and second a primary chemotherapy approach after surgery - had to be terminated prematurely due to unacceptably high relapse rates suggesting that craniospinal irradiation remains an integral component of treatment. The presence of TP53 mutations and OTX2 gains have recently been reported as independent negative prognostic factors in a multi-institutional cohort of WNT-pathway medulloblastoma raising questions on eligibility of such patients for de-escalation trials. The definition of low-risk WNT-pathway medulloblastoma may need to be refined in light of recent clinical data and newer biological information.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cerebellar NeoplasmsMedulloblastomaAdolescentChildHumansYoung AdultNeoplasm Recurrence, LocalProspective StudiesRisk FactorsWnt Signaling Pathway

Stichwörter der Autor:innen

de-intensificationmedulloblastomamolecularsurvivaltoxicity

Autor:innen und Institutionen

  • Department of Radiation Oncology, ACTREC/TMH, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra 410210, India.
  • Department of Neuro-Oncology Laboratory, ACTREC/TMH, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra 410210, India.
  • Department of Pathology, ACTREC/TMH, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra 410210, India.
  • Department of Pediatric Oncology, ACTREC/TMH, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra 410210, India.

Zitieren

APA

Mani, S., Chatterjee, A., Dasgupta, A., Shirsat, N., Epari, S., Chinnaswamy, G., & Gupta, T. (2023). WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go?. Oncotarget, 14(1), 105-110. https://doi.org/10.18632/oncotarget.28360

Vancouver

Mani S, Chatterjee A, Dasgupta A, Shirsat N, Epari S, Chinnaswamy G, et al. WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go?. Oncotarget. 2023;14(1):105-110. doi:10.18632/oncotarget.28360

BibTeX
@article{Mani2023,
  author = {Mani, Shakthivel and Chatterjee, Abhishek and Dasgupta, Archya and Shirsat, Neelam and Epari, Sridhar and Chinnaswamy, Girish and Gupta, Tejpal},
  title = {WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go?},
  journal = {Oncotarget},
  year = {2023},
  volume = {14},
  number = {1},
  pages = {105--110},
  doi = {10.18632/oncotarget.28360}
}
Kostenlos starten →